An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development, net

Marketing expenses

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Alpha Tau Medical

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company. It focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

JERUSALEM, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will participate in person at three upcoming investor conferences in September 2022.

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

- Received FDA Conditional Investigational Device Exemption (IDE) , whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT ™ in recurrent cutaneous squamous cell carcinoma . The Company expects to treat its first patient in this study later in 2022 -

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it will host a hybrid in-person/virtual key opinion leader (KOL) meeting at Convene (North Hub Room), located at 530 5th Ave. New York, NY on Monday, July 18, 2022 beginning at 10:30 am Eastern Time. For those attending in-person, breakfast will begin at 10:30 am Eastern Time. For those attending virtually, the presentations and webcast will begin at 11:00 am Eastern Time.

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

JERUSALEM , June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patient was treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer at the Rambam Health Care Center in Haifa, Israel.

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

Amylyx Pharmaceuticals

Novo Nordisk

Regeneron Pharmaceuticals

As the industry continues to make new discoveries, could biotech stocks be in focus?

4 Top Biotech Stocks To Watch Today

JERUSALEM , June 8, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the Company's Investigational Device Exemption (IDE) application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using the Alpha DaRT.

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

JERUSALEM , June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr.

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds- -Targeted start of U.S. multi-center pivotal trial in skin cancers in the middle of 2022- JERUSALEM , May 26, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ: DRTS) (NASDAQ: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2022 financial results and provided a corporate update.

Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM , May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW) , the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patients in its French multicenter trial for skin cancer were treated with Alpha DaRT, at the Leon Berard Center in Lyon, France by Dr. Pascal Pommier and his team. The Leon Berard Center specializes in radiotherapy for cancer and is affiliated with the National Federation of Cancer Centers in France - UNICANCER Group.

First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial

Alpha Tau Medical's proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers.

Alpha Tau: Treating Cancer With Precision Alpha Radiation

JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2021 financial results and provided a corporate update.

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update

Allego NV

Forge Global Holdings Inc

Leafly Holdings

JX Luxventure Ltd

Miromatrix Medical Inc

NeuroSense Therapeutics Ltd

Kidpik Corp

Society Pass

SciSparc Ltd

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

12 Stocks Halted On A Circuit Breaker This Week

Why Alpha Tau Medical Stock Skyrocketed Today

News for Alpha Tau Medical Stock (DRTS)